Hikal share price
You have to be logged in to add this to Watchlist.- ₹210.90(-1.08%)May 8, 2026 15:47:28 PM IST
- NSE
- BSE
- Vol : 358.15 K (NSE + BSE)Last 20 day avg : 352.79 K
Hikal is trading -1.08% lower at Rs 210.90 as compared to its last closing price. Hikal has been trading in the price range of 217.70 & 210.00. Hikal has given -6.14% in this year & 12.56% in the last 5 days. There are 2 analysts who have initiated coverage on Hikal. There are 1 analysts who have given it a strong buy rating & 0.00 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of -5.90 Crores in its last quarter.Listed peers of Hikal include Cipla (-1.11%), Sun Pharmaceutical Industries (0.70%), Divi's Laboratories (0.12%).The Mutual Fund holding in Hikal was at 5.92% in 31 Mar 2026. The MF holding has increased from the last quarter. The FII holding in Hikal was at 1.44% in 31 Mar 2026. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Updated on May 10, 2026, 03:04 PM UTC
- BetaHigh volatility1.79Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.61The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.47Annual dividends as a percentage of the stock price.
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Cipla | Neutral | 1,347.70 | -1.11 | 1,09,012.85 | 22.95 | 3.87 | 0.87 | 0.81 |
| Sun Pharmaceutical Industries | Bullish | 1,847.30 | 0.70 | 4,43,968.98 | 36.24 | 5.77 | 0.92 | 0.50 |
| Divi's Laboratories | Bullish | 6,708.90 | 0.12 | 1,78,626.71 | 78.61 | 11.52 | 0.46 | 0.01 |
| Dr Reddy's Laboratories | Bullish | 1,293.00 | -1.06 | 1,07,899.58 | 18.63 | 3.14 | 0.63 | 2.34 |
| Torrent Pharmaceuticals | Bullish | 4,376.45 | 0.40 | 1,48,363.17 | 67.32 | 17.1 | 0.83 | 17.62 |
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-02-11 | Quarterly Results & Interim Dividend |
| 2025-11-13 | Quarterly Results |
| 2025-11-06 | Quarterly Results |
| 2025-08-07 | Quarterly Results |
| 2025-05-14 | Audited Results & Final Dividend |
- IndustryBiotechnology & Drugs
- ISININE475B01022
- BSE Code524735
- NSE CodeHIKAL
Hikal is trading at 210.90 as on Fri May 08 2026 10:17:28. This is -1.08% lower as compared to its previous closing price of 213.20.
The market capitalization of Hikal is 2600.41 Cr as on Fri May 08 2026 10:17:28.
The average broker rating on Hikal is Buy. The breakup of analyst rating is given below -
- 1 analysts have given a strong buy rating
- 0.00 analysts have given a buy rating
- 1 analysts have given a hold rating
- 0.00 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Hikal is 449.30 whereas the 52 wk low is 145.95
Hikal can be analyzed on the following key metrics -
- TTM P/E:
- Sector P/E: 24.71
- Dividend Yield: 0.47%
- D/E ratio: -
Hikal reported a net profit of 90.80 Cr in 2025.
The Mutual Fund Shareholding was 5.92% at the end of 31 Mar 2026.
EQUITY QUICK LINKS
Hikal QUICK LINKS
FROM MARKETS
RELATED LINKS
Quarterly Results
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.